Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
$0.53
-2.7%
$0.50
$0.38
$269.28
$5.63M0.38867,497 shs235,434 shs
Onconetix, Inc. stock logo
ONCO
Onconetix
$0.07
-14.0%
$0.08
$0.05
$21.40
$4.68M3.497.99 million shs9.68 million shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.21
-3.3%
$2.91
$1.75
$9.37
$5.19M1.66841,335 shs19,216 shs
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
$0.54
-0.5%
$0.68
$0.47
$6.30
$2.58M0.671.42 million shs56,322 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-2.73%+6.80%+21.39%-93.83%-99.63%
Onconetix, Inc. stock logo
ONCO
Onconetix
-14.00%-14.40%+8.70%-81.92%-98.82%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-3.31%-0.62%-18.73%+34.31%+1,719.73%
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
-0.50%+3.27%-23.73%-55.74%-87.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
2.9252 of 5 stars
3.50.00.00.02.61.71.9
Onconetix, Inc. stock logo
ONCO
Onconetix
0.2317 of 5 stars
0.02.00.00.01.90.00.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.1702 of 5 stars
0.02.00.00.02.60.00.0
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
0.6364 of 5 stars
0.04.00.00.02.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
3.00
Buy$360.0067,315.73% Upside
Onconetix, Inc. stock logo
ONCO
Onconetix
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/A($4.12) per shareN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
$1.87M2.50N/AN/A$3.01 per share0.02
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.97M0.37N/AN/A$3.01 per share1.07
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
N/AN/AN/AN/A$88.98 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-$36.63M$298.122.97N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)
Onconetix, Inc. stock logo
ONCO
Onconetix
-$37.41MN/A0.00N/A-2,758.89%N/A-48.09%5/26/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$4.84M-$4.02N/AN/AN/A-26.82%-68.98%-26.39%6/16/2025 (Estimated)
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
-$98.30MN/A0.00N/AN/AN/A-224.85%-103.22%8/7/2025 (Estimated)

Latest ZVSA, AEON, ONCO, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
-$0.40-$0.73-$0.33-$0.73N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/A
0.22
0.22
Onconetix, Inc. stock logo
ONCO
Onconetix
N/A
0.06
0.05
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.34
2.49
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
N/A
0.03
0.03

Institutional Ownership

CompanyInstitutional Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
22.78%
Onconetix, Inc. stock logo
ONCO
Onconetix
23.89%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
3.91%

Insider Ownership

CompanyInsider Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
0.86%
Onconetix, Inc. stock logo
ONCO
Onconetix
3.10%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
0.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
510.53 million74.37 millionNot Optionable
Onconetix, Inc. stock logo
ONCO
Onconetix
1264.55 million57.17 millionN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.62 million1.55 millionNot Optionable
ZyVersa Therapeutics, Inc. stock logo
ZVSA
ZyVersa Therapeutics
24.77 million2.34 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON Biopharma stock logo

AEON Biopharma NASDAQ:AEON

$0.53 -0.02 (-2.73%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$0.55 +0.02 (+3.00%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Onconetix stock logo

Onconetix NASDAQ:ONCO

$0.07 -0.01 (-14.00%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$0.07 0.00 (-4.97%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.21 -0.11 (-3.31%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$3.22 +0.00 (+0.16%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

ZyVersa Therapeutics stock logo

ZyVersa Therapeutics NASDAQ:ZVSA

$0.54 0.00 (-0.50%)
Closing price 05/23/2025 03:53 PM Eastern
Extended Trading
$0.54 -0.01 (-0.93%)
As of 05/23/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.